A trial to evaluate the safety, immunogenicity and clinical activity of a helper peptide vaccine plus PD-1 blockade

被引：0
|
作者：
Slingluff, Craig, Jr. [1 ]
Gaughan, Elizabeth [1 ]
Grosh, William [1 ]
Petroni, Gina [1 ]
Bullock, Kimberly [1 ]
机构：
[1] Univ Virginia, Charlottesville, VA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P227
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A TRIAL TO EVALUATE THE SAFETY, IMMUNOGENICITY, AND CLINICAL ACTIVITY OF A HELPER PEPTIDE VACCINE PLUS PD-1 BLOCKADE (MEL64, PATHVACS: PD-1 ANTIBODY AND T-HELPER VACCINE AND CORRELATIVE STUDIES)
    Slingluff, Craig
    Chianese-Bullock, Kimberly
    Mauldin, Ileana
    Olson, Walter
    Smith, Kelly
    Dengel, Lynn
    Haden, Kathleen
    Gaughan, Elizabeth
    Kaur, Varinder
    Grosh, William
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A421 - A421
  • [2] Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naive and PD-1 antibody-experienced patients with melanoma (MEL64)
    Vavolizza, Rick Daniel
    Petroni, Gina R.
    Mauldin, Ileana S.
    Chianese-Bullock, Kimberly A.
    Olson, Walter C.
    Smith, Kelly T.
    Dengel, Lynn T.
    Haden, Kathleen
    Grosh, William W.
    Kaur, Varinder
    Varhegyi, Nikole
    Gaughan, Elizabeth M.
    Slingluff, Craig L., Jr.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (09)
  • [3] A trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)
    Slingluff, Craig
    Petroni, Gina
    Chianese-Bullock, Kimberly
    Wages, Nolan
    Olson, Walter
    Smith, Kelly
    Dengel, Lynn
    Dickinson, Anna
    Reed, Caroline
    Gaughan, Elizabeth
    Grosh, William
    Kaur, Varinder
    Varhegyi, Nikole
    Smolkin, Mark
    Galeassi, Nadejda
    Deacon, Donna
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [4] Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)
    Slingluff, Craig L., Jr.
    Petroni, Gina R.
    Chianese-Bullock, Kimberly A.
    Wages, Nolan A.
    Olson, Walter C.
    Smith, Kelly T.
    Haden, Kathleen
    Dengel, Lynn T.
    Dickinson, Anna
    Reed, Caroline
    Gaughan, Elizabeth M.
    Grosh, William W.
    Kaur, Varinder
    Varhegyi, Nikole
    Smolkin, Mark
    Galeassi, Nadejda, V
    Deacon, Donna
    Hall, Emily H.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (01)
  • [5] Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naive and PD-1 antibody-experienced patients with melanoma (MEL64) (vol 10, e005424, 2022)
    Vavolizza, R. D.
    Petroni, G. R.
    Mauldin, I. S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (11)
  • [6] Safety and immunogenicity of ricin vaccine, RVEC™, in a Phase 1 clinical trial
    Pittman, Phillip R.
    Reisler, Ronald B.
    Lindsey, Changhong Y.
    Gueerena, Fernando
    Rivard, Robert
    Clizbe, Denise P.
    Chambers, Matthew
    Norris, Sarah
    Smith, Leonard A.
    VACCINE, 2015, 33 (51) : 7299 - 7306
  • [7] An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors
    Poulet, Frederique M.
    Wolf, Jayanthi J.
    Herzyk, Danuta J.
    DeGeorge, Joseph J.
    BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY, 2016, 107 (02) : 108 - 119
  • [8] PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
    Xu-Monette, Zijun Y.
    Zhou, Jianfeng
    Young, Ken H.
    BLOOD, 2018, 131 (01) : 68 - 83
  • [9] CANCER VACCINE PLUS PD-1 BLOCKADE PROMOTES INFILTRATION OF MELANOMA METASTASES BY VACCINE-INDUCED T LYMPHOCYTES
    Tran, Christine
    Schwartzman, Gabrielle
    Olson, Walter
    Smith, Kelly
    Bryant, Jennifer
    Slingluff, Craig
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1533 - A1533
  • [10] PD-1 and PD-L1 Blockade plus Chemotherapy in Endometrial Cancer
    Polak, Paz
    Fu, Lili
    Foulkes, William D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (09): : 866 - 868
12345